About EDAP TMS
EDAP TMS is the world leader in therapeutic ultrasound
Having been present in the market for more than 30 years, EDAP TMS (NASDAQ : EDAP) develops minimally-invasive therapeutic solutions for urology.
By consistently investing in Research & Development (R&D) and by forming partnerships with internationally-renowned medical research institutions, EDAP TMS has been able to patent innovative technologies. EDAP TMS is present in many countries through an extensive network of subsidiaries and distribution partners. The company focuses on producing a high standard of service for health care practitioners: mobile equipment, training centers, maintenance network.
With Ablatherm® HIFU, EDAP TMS is the world leader in High Intensity Focused Ultrasound (HIFU) for localized prostate cancer treatment. The company is currently adapting this technology so that it is potentially able to treat other types of tumors.
As a pioneer and key player in the field of extracorporeal lithotripsy (ESWL), EDAP TMS introduced the first modular lithotripter and owns the patent for Electroconductive technology, the 4th generation shock wave source, utilized in its Sonolith® range of ESWL systems.
EDAP TMS focuses every day on delivering technologies that guarantee reproducible positive outcomes with low side effects and preserved quality of life.